Received Aug 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 7975C | IM |
Intramuscular administration; This non-serious case was reported by a nurse via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 73-year-old male patient who received MMR (Priorix) (batch number 7975C, expiry date 01-MAR-2027) for prophylaxis. On 01-AUG-2025, the patient received Priorix (intramuscular). On 01-AUG-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Intramuscular administration). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 01-AUG-2025 The registered nurse reported that an adult received a Priorix intramuscularly today (date of reporting), which led to Subcutaneous injection formulation administered by other route.